Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEAK: KSI-101 in Macular Edema Secondary to Inflammation
NCT06990399Phase 3Recruiting
- Sponsor
- Kodiak Sciences
- Start
- Jul 2025
- Primary completion
- Apr 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of tabirafusp alfa in macular edema (3 arms), sponsored by Kodiak Sciences. Primary endpoint: Best Corrected Visual Acuity at 24 weeks. Started Jul 2025; status: recruiting.
02
Drugs
tabirafusp alfa
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT06990399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06990399.